Skip to main content

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Estudio de la quasiespecies del gen X en ARN circulante del virus de la hepatitis B (ARN-VHB): en búsqueda de nuevos factores pronósticos y dianas para terapia génica

IP: Francisco Rodríguez Frias
Collaborators: Noelia Díaz Troyano
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: INT19/00060
Duration: 01/06/2020 - 30/06/2021

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Estrella Caballero Requero

Estrella Caballero Requero

Microbiology
Read more
Brigidi , Serena

Brigidi , Serena

Main researcher
Maternal and Fetal Medicine
Read more
Martincic , Markus

Martincic , Markus

Tècnic/a Grau Superior
International Projects Unit
Competitive Projects Area
Read more
Lluis Armadans Gil

Lluis Armadans Gil

Main researcher
Epidemiology and Public Health
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.